Authors: Sharon Salt, Editor
Previous research has demonstrated that tau load and distribution are directly correlated with disease progression in Alzheimer’s. This has piqued the interest of researchers in the field to turn to tau as a potential therapeutic target for the disease. Although developments that are currently in the clinic focus more on intervening after tau proteins have misfolded and oligomers have formed, a new study has indicated that utilizing a tau inhibitor to target the first step of this process may be emerging.
Oligomerix (NY, USA) and the Feinstein Institutes for Medical Research (NY, USA) have announced the publication of preclinical data on a tau inhibitor, which demonstrates that the oral small molecule drug may inhibit the formation of neurotoxic tau oligomers in a mouse model of tau aggregation most relevant to Alzheimer’s disease.